\documentclass[11pt,twoside]{article}\makeatletter \IfFileExists{xcolor.sty}% {\RequirePackage{xcolor}}% {\RequirePackage{color}} \usepackage{colortbl} \usepackage{wrapfig} \usepackage{ifxetex} \ifxetex \usepackage{fontspec} \usepackage{xunicode} \catcode`⃥=\active \def⃥{\textbackslash} \catcode`❴=\active \def❴{\{} \catcode`❵=\active \def❵{\}} \def\textJapanese{\fontspec{Noto Sans CJK JP}} \def\textChinese{\fontspec{Noto Sans CJK SC}} \def\textKorean{\fontspec{Noto Sans CJK KR}} \setmonofont{DejaVu Sans Mono} \else \IfFileExists{utf8x.def}% {\usepackage[utf8x]{inputenc} \PrerenderUnicode{–} }% {\usepackage[utf8]{inputenc}} \usepackage[english]{babel} \usepackage[T1]{fontenc} \usepackage{float} \usepackage[]{ucs} \uc@dclc{8421}{default}{\textbackslash } \uc@dclc{10100}{default}{\{} \uc@dclc{10101}{default}{\}} \uc@dclc{8491}{default}{\AA{}} \uc@dclc{8239}{default}{\,} \uc@dclc{20154}{default}{ } \uc@dclc{10148}{default}{>} \def\textschwa{\rotatebox{-90}{e}} \def\textJapanese{} \def\textChinese{} \IfFileExists{tipa.sty}{\usepackage{tipa}}{} \fi \def\exampleFont{\ttfamily\small} \DeclareTextSymbol{\textpi}{OML}{25} \usepackage{relsize} \RequirePackage{array} \def\@testpach{\@chclass \ifnum \@lastchclass=6 \@ne \@chnum \@ne \else \ifnum \@lastchclass=7 5 \else \ifnum \@lastchclass=8 \tw@ \else \ifnum \@lastchclass=9 \thr@@ \else \z@ \ifnum \@lastchclass = 10 \else \edef\@nextchar{\expandafter\string\@nextchar}% \@chnum \if \@nextchar c\z@ \else \if \@nextchar l\@ne \else \if \@nextchar r\tw@ \else \z@ \@chclass \if\@nextchar |\@ne \else \if \@nextchar !6 \else \if \@nextchar @7 \else \if \@nextchar (8 \else \if \@nextchar )9 \else 10 \@chnum \if \@nextchar m\thr@@\else \if \@nextchar p4 \else \if \@nextchar b5 \else \z@ \@chclass \z@ \@preamerr \z@ \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi} \gdef\arraybackslash{\let\\=\@arraycr} \def\@textsubscript#1{{\m@th\ensuremath{_{\mbox{\fontsize\sf@size\z@#1}}}}} \def\Panel#1#2#3#4{\multicolumn{#3}{){\columncolor{#2}}#4}{#1}} \def\abbr{} \def\corr{} \def\expan{} \def\gap{} \def\orig{} \def\reg{} \def\ref{} \def\sic{} \def\persName{}\def\name{} \def\placeName{} \def\orgName{} \def\textcal#1{{\fontspec{Lucida Calligraphy}#1}} \def\textgothic#1{{\fontspec{Lucida Blackletter}#1}} \def\textlarge#1{{\large #1}} \def\textoverbar#1{\ensuremath{\overline{#1}}} \def\textquoted#1{‘#1’} \def\textsmall#1{{\small #1}} \def\textsubscript#1{\@textsubscript{\selectfont#1}} \def\textxi{\ensuremath{\xi}} \def\titlem{\itshape} \newenvironment{biblfree}{}{\ifvmode\par\fi } \newenvironment{bibl}{}{} \newenvironment{byline}{\vskip6pt\itshape\fontsize{16pt}{18pt}\selectfont}{\par } \newenvironment{citbibl}{}{\ifvmode\par\fi } \newenvironment{docAuthor}{\ifvmode\vskip4pt\fontsize{16pt}{18pt}\selectfont\fi\itshape}{\ifvmode\par\fi } \newenvironment{docDate}{}{\ifvmode\par\fi } \newenvironment{docImprint}{\vskip 6pt}{\ifvmode\par\fi } \newenvironment{docTitle}{\vskip6pt\bfseries\fontsize{22pt}{25pt}\selectfont}{\par } \newenvironment{msHead}{\vskip 6pt}{\par} \newenvironment{msItem}{\vskip 6pt}{\par} \newenvironment{rubric}{}{} \newenvironment{titlePart}{}{\par } \newcolumntype{L}[1]{){\raggedright\arraybackslash}p{#1}} \newcolumntype{C}[1]{){\centering\arraybackslash}p{#1}} \newcolumntype{R}[1]{){\raggedleft\arraybackslash}p{#1}} \newcolumntype{P}[1]{){\arraybackslash}p{#1}} \newcolumntype{B}[1]{){\arraybackslash}b{#1}} \newcolumntype{M}[1]{){\arraybackslash}m{#1}} \definecolor{label}{gray}{0.75} \def\unusedattribute#1{\sout{\textcolor{label}{#1}}} \DeclareRobustCommand*{\xref}{\hyper@normalise\xref@} \def\xref@#1#2{\hyper@linkurl{#2}{#1}} \begingroup \catcode`\_=\active \gdef_#1{\ensuremath{\sb{\mathrm{#1}}}} \endgroup \mathcode`\_=\string"8000 \catcode`\_=12\relax \usepackage[a4paper,twoside,lmargin=1in,rmargin=1in,tmargin=1in,bmargin=1in,marginparwidth=0.75in]{geometry} \usepackage{framed} \definecolor{shadecolor}{gray}{0.95} \usepackage{longtable} \usepackage[normalem]{ulem} \usepackage{fancyvrb} \usepackage{fancyhdr} \usepackage{graphicx} \usepackage{marginnote} \renewcommand{\@cite}[1]{#1} \renewcommand*{\marginfont}{\itshape\footnotesize} \def\Gin@extensions{.pdf,.png,.jpg,.mps,.tif} \pagestyle{fancy} \usepackage[pdftitle={DNA Normality Following in Vitro Sperm Preparation with Pentoxifylline and L-Carnitine for Asthenozoospermic Infertile Men}, pdfauthor={}]{hyperref} \hyperbaseurl{} \paperwidth210mm \paperheight297mm \def\@pnumwidth{1.55em} \def\@tocrmarg {2.55em} \def\@dotsep{4.5} \setcounter{tocdepth}{3} \clubpenalty=8000 \emergencystretch 3em \hbadness=4000 \hyphenpenalty=400 \pretolerance=750 \tolerance=2000 \vbadness=4000 \widowpenalty=10000 \renewcommand\section{\@startsection {section}{1}{\z@}% {-1.75ex \@plus -0.5ex \@minus -.2ex}% {0.5ex \@plus .2ex}% {\reset@font\Large\bfseries}} \renewcommand\subsection{\@startsection{subsection}{2}{\z@}% {-1.75ex\@plus -0.5ex \@minus- .2ex}% {0.5ex \@plus .2ex}% {\reset@font\Large}} \renewcommand\subsubsection{\@startsection{subsubsection}{3}{\z@}% {-1.5ex\@plus -0.35ex \@minus -.2ex}% {0.5ex \@plus .2ex}% {\reset@font\large}} \renewcommand\paragraph{\@startsection{paragraph}{4}{\z@}% {-1ex \@plus-0.35ex \@minus -0.2ex}% {0.5ex \@plus .2ex}% {\reset@font\normalsize}} \renewcommand\subparagraph{\@startsection{subparagraph}{5}{\parindent}% {1.5ex \@plus1ex \@minus .2ex}% {-1em}% {\reset@font\normalsize\bfseries}} \def\l@section#1#2{\addpenalty{\@secpenalty} \addvspace{1.0em plus 1pt} \@tempdima 1.5em \begingroup \parindent \z@ \rightskip \@pnumwidth \parfillskip -\@pnumwidth \bfseries \leavevmode #1\hfil \hbox to\@pnumwidth{\hss #2}\par \endgroup} \def\l@subsection{\@dottedtocline{2}{1.5em}{2.3em}} \def\l@subsubsection{\@dottedtocline{3}{3.8em}{3.2em}} \def\l@paragraph{\@dottedtocline{4}{7.0em}{4.1em}} \def\l@subparagraph{\@dottedtocline{5}{10em}{5em}} \@ifundefined{c@section}{\newcounter{section}}{} \@ifundefined{c@chapter}{\newcounter{chapter}}{} \newif\if@mainmatter \@mainmattertrue \def\chaptername{Chapter} \def\frontmatter{% \pagenumbering{roman} \def\thechapter{\@roman\c@chapter} \def\theHchapter{\roman{chapter}} \def\thesection{\@roman\c@section} \def\theHsection{\roman{section}} \def\@chapapp{}% } \def\mainmatter{% \cleardoublepage \def\thechapter{\@arabic\c@chapter} \setcounter{chapter}{0} \setcounter{section}{0} \pagenumbering{arabic} \setcounter{secnumdepth}{6} \def\@chapapp{\chaptername}% \def\theHchapter{\arabic{chapter}} \def\thesection{\@arabic\c@section} \def\theHsection{\arabic{section}} } \def\backmatter{% \cleardoublepage \setcounter{chapter}{0} \setcounter{section}{0} \setcounter{secnumdepth}{2} \def\@chapapp{\appendixname}% \def\thechapter{\@Alph\c@chapter} \def\theHchapter{\Alph{chapter}} \appendix } \newenvironment{bibitemlist}[1]{% \list{\@biblabel{\@arabic\c@enumiv}}% {\settowidth\labelwidth{\@biblabel{#1}}% \leftmargin\labelwidth \advance\leftmargin\labelsep \@openbib@code \usecounter{enumiv}% \let\p@enumiv\@empty \renewcommand\theenumiv{\@arabic\c@enumiv}% }% \sloppy \clubpenalty4000 \@clubpenalty \clubpenalty \widowpenalty4000% \sfcode`\.\@m}% {\def\@noitemerr {\@latex@warning{Empty `bibitemlist' environment}}% \endlist} \def\tableofcontents{\section*{\contentsname}\@starttoc{toc}} \parskip0pt \parindent1em \def\Panel#1#2#3#4{\multicolumn{#3}{){\columncolor{#2}}#4}{#1}} \newenvironment{reflist}{% \begin{raggedright}\begin{list}{} {% \setlength{\topsep}{0pt}% \setlength{\rightmargin}{0.25in}% \setlength{\itemsep}{0pt}% \setlength{\itemindent}{0pt}% \setlength{\parskip}{0pt}% \setlength{\parsep}{2pt}% \def\makelabel##1{\itshape ##1}}% } {\end{list}\end{raggedright}} \newenvironment{sansreflist}{% \begin{raggedright}\begin{list}{} {% \setlength{\topsep}{0pt}% \setlength{\rightmargin}{0.25in}% \setlength{\itemindent}{0pt}% \setlength{\parskip}{0pt}% \setlength{\itemsep}{0pt}% \setlength{\parsep}{2pt}% \def\makelabel##1{\upshape ##1}}% } {\end{list}\end{raggedright}} \newenvironment{specHead}[2]% {\vspace{20pt}\hrule\vspace{10pt}% \phantomsection\label{#1}\markright{#2}% \pdfbookmark[2]{#2}{#1}% \hspace{-0.75in}{\bfseries\fontsize{16pt}{18pt}\selectfont#2}% }{} \def\TheFullDate{2013-01-15 (revised: 15 January 2013)} \def\TheID{\makeatother } \def\TheDate{2013-01-15} \title{DNA Normality Following in Vitro Sperm Preparation with Pentoxifylline and L-Carnitine for Asthenozoospermic Infertile Men} \author{}\makeatletter \makeatletter \newcommand*{\cleartoleftpage}{% \clearpage \if@twoside \ifodd\c@page \hbox{}\newpage \if@twocolumn \hbox{}\newpage \fi \fi \fi } \makeatother \makeatletter \thispagestyle{empty} \markright{\@title}\markboth{\@title}{\@author} \renewcommand\small{\@setfontsize\small{9pt}{11pt}\abovedisplayskip 8.5\p@ plus3\p@ minus4\p@ \belowdisplayskip \abovedisplayskip \abovedisplayshortskip \z@ plus2\p@ \belowdisplayshortskip 4\p@ plus2\p@ minus2\p@ \def\@listi{\leftmargin\leftmargini \topsep 2\p@ plus1\p@ minus1\p@ \parsep 2\p@ plus\p@ minus\p@ \itemsep 1pt} } \makeatother \fvset{frame=single,numberblanklines=false,xleftmargin=5mm,xrightmargin=5mm} \fancyhf{} \setlength{\headheight}{14pt} \fancyhead[LE]{\bfseries\leftmark} \fancyhead[RO]{\bfseries\rightmark} \fancyfoot[RO]{} \fancyfoot[CO]{\thepage} \fancyfoot[LO]{\TheID} \fancyfoot[LE]{} \fancyfoot[CE]{\thepage} \fancyfoot[RE]{\TheID} \hypersetup{citebordercolor=0.75 0.75 0.75,linkbordercolor=0.75 0.75 0.75,urlbordercolor=0.75 0.75 0.75,bookmarksnumbered=true} \fancypagestyle{plain}{\fancyhead{}\renewcommand{\headrulewidth}{0pt}} \date{} \usepackage{authblk} \providecommand{\keywords}[1] { \footnotesize \textbf{\textit{Index terms---}} #1 } \usepackage{graphicx,xcolor} \definecolor{GJBlue}{HTML}{273B81} \definecolor{GJLightBlue}{HTML}{0A9DD9} \definecolor{GJMediumGrey}{HTML}{6D6E70} \definecolor{GJLightGrey}{HTML}{929497} \renewenvironment{abstract}{% \setlength{\parindent}{0pt}\raggedright \textcolor{GJMediumGrey}{\rule{\textwidth}{2pt}} \vskip16pt \textcolor{GJBlue}{\large\bfseries\abstractname\space} }{% \vskip8pt \textcolor{GJMediumGrey}{\rule{\textwidth}{2pt}} \vskip16pt } \usepackage[absolute,overlay]{textpos} \makeatother \usepackage{lineno} \linenumbers \begin{document} \author[1]{Saad S. Al-Dujaily} \renewcommand\Authands{ and } \date{\small \em Received: 15 December 2012 Accepted: 2 January 2013 Published: 15 January 2013} \maketitle \begin{abstract} Background: Sperm cells from infertile patients have poor motility and defected DNA. Pentoxifylline (PX) and L-carnitine (LC) are added in the medium for in vitro activation to increase sperm motility and improve the pregnancy outcome. However, there are few studies about the effect of PX with LC medium on sperm DNA normality.Objective: The goal of this study is to found out the optimum medium can increase the active motility percentage and reduce sperm DNA damage for asthenozoospermic men using the motility stimulant substances, PX and LC for this purpose.Methods: Semen was collected from 100 infertile men involved in the current study. Each semen sample was divided into four portions. One part was considered as a control group and in vitro activated by using culture medium only. The other portions were considered as treated groups and in vitro activated by adding PX (1mg) and/or LC (0.5mg) to the culture medium. Certain sperm function parameters were examined before and following in vitro activation using layering technique. Sperms DNA damage was detected by using acridine orange (AO) test. \end{abstract} \keywords{pentoxifylline, l-carnitine, in vitro activation, layering preparation technique, male infertility.} \begin{textblock*}{18cm}(1cm,1cm) % {block width} (coords) \textcolor{GJBlue}{\LARGE Global Journals \LaTeX\ JournalKaleidoscope\texttrademark} \end{textblock*} \begin{textblock*}{18cm}(1.4cm,1.5cm) % {block width} (coords) \textcolor{GJBlue}{\footnotesize \\ Artificial Intelligence formulated this projection for compatibility purposes from the original article published at Global Journals. However, this technology is currently in beta. \emph{Therefore, kindly ignore odd layouts, missed formulae, text, tables, or figures.}} \end{textblock*} \let\tabcellsep& \section[{Introduction}]{Introduction}\par nfertility is the inability of a sexually active noncontraception couple to achieve pregnancy in one year {\ref (WHO ,2010)} . A male factor is solely responsible in about 20\% of infertile couples and contributory in another 30-40\%, if a male infertility factor is present, it is almost always defined by the finding of an abnormal semen analysis for the assessment of male fertility \hyperref[b2]{(Agarwal et al.,2003)}. Problems with the production and maturation of sperm are the most common causes of male infertility. Sperm may be immature, abnormally shaped, or unable to move properly. But, normal sperm may be produced in abnormally low numbers (oligozoospermia) or seemingly not at all (azoospermia) \hyperref[b15]{(Diemer et al., 2000)}.\par Asthenozoospermia is one of the major causes of infertility or reduced fertility in men \hyperref[b3]{(4)}. Motility is the prime functional parameter that determines the fertilizing ability of spermatozoa, the cause underlying loss of sperm motility may be either hormonal, biochemical, immunological or infection \hyperref[b19]{(Henkel and Schill, 2003;}\hyperref[b37]{Twigg et al., 1998)}.\par Semen preparation techniques for assisted reproduction were developed to concentrate progressively motile, functional and morphologically normal spermatozoa, and to remove defective and non vital sperms as well as cells e.g. spermatogenic cells and leukocytes.\par Leucocytes, bacteria and dead spermatozoa produce oxygen radicals that negatively influence the ability to fertilize the egg \hyperref[b11]{(Aviad and Dettelbache, 1984)}. Layering technique is used for normospermic and asthenospermic semen, which allow self-selection of motile sperm.Two factors protect the sperm DNA from oxidative insult: the characteristic tight packaging of the DNA; and the antioxidants present in seminal plasma \hyperref[b34]{(Stanic et al, 2002)}.\par On the other hand, pentoxifylline is dimethylexanthine derivative designated chemically as 1-(5oxohexyl)-3, 7-dimethylexanthine {\ref (Okada,1997)}.The PX prevents cAMP breakdown by inhibiting the activity of the cAMP phosphodiesterase and presumably, stimulates sperm motion \hyperref[b35]{(Steiber et al.,2004)}. Moreover, PX has a protective effect on sperm membranes (i.e.it would preserve functional membrane integrity of sperm tail) as it scavenges ROS and then reduces lipid peroxidation \hyperref[b24]{(Muller et al 2002)}.\par Moreover, L-carnitine is a quaternary ammonium compound biosynthesize from the amino acids lysine and methionine \hyperref[b12]{(Claudette and Lawrence, 1996)}. In human body, the primary L-carnitine function is to carry fatty acids into the mitochondria where they can be broken down with the ultimate production of energy \hyperref[b26]{(Oosterhuis et al., 2000)}. In the epididymis, the sperm use fatty acids as a source of metabolic energy and scientists believe that one of the functions of LC in sperm is to carry fatty acids into the sperm mitochondria, thereby assisting in the production of energy. Secondly, the conversion of some of the LC to ALC in the mature sperm facilitates the continuation of energy production within the sperm and the newly formed ALC serves as a readily available source of acetyl groups, i.e. energy, for the sperm \hyperref[b31]{(Sills, 2004)}.\par A number of studies have investigated the relationship between human sperm DNA damage and semen parameters, such as concentration, motility and morphology (Gil-Guzman et al, 2001 {\ref ;}\hyperref[b30]{Sikka, 2001)}. Oxidative stress (OS) may develop as a result of an imbalance between ROS generation and antioxidant scavenging activities \hyperref[b13]{(Cocuzza et al., 2007)}. Sperm preparation techniques can be used to decrease ROS damage production to enhance and maintain sperm quality after ejaculation (WHO, 1999). Therefore the aim of the present study was to use PX and LC for stimulate certain sperm functions and protect the male germ cell from the influence of free radicals. \section[{II.}]{II.} \section[{Material and Methods}]{Material and Methods}\par Semen samples were obtained from 100 infertile men during their attendance to the IVF High Institute, Al-Nahrain University through the period from November 2011 to October 2012. The samples of seminal fluid were collected after 3 to 5 days of abstinence directly into a clean, dry and sterile disposable Petri-dishes by masturbation in a room near the laboratory. After liquefaction time, macroscopic and microscopic analysis of semen samples was don using standardization of WHO (1999) to determine certain sperm function parameters namely; sperm concentration (million/ml), percentage of sperm motility and morphologically normal sperm (MNS) percentage. The DNA denaturation was examined by using acridine orange test according to \hyperref[b36]{Tejada, et al. (1984)}. \section[{a) Preparation of Pentoxifylline Stock Solution}]{a) Preparation of Pentoxifylline Stock Solution}\par This solution was prepared by dissolving 10 mg from PX powder (sigma, USA) in 10 ml of PBS (0.1\%) then stirring until dissolve. These concentrations prepared daily under sterile condition using UV light and Millipore filter (0.45?M). \section[{b) Preparation of L-Carnitine Stock Solution}]{b) Preparation of L-Carnitine Stock Solution}\par This solution was prepared by adding 0.5mg of LC powder (Natrol,USA) to 10 ml of phosphate buffer solution in plastic test tube . Then it was filtered by using Millipore 0.45 µM and have been fixed at pH 7.4-7.8 at 25?C. \section[{c) In vitro activation technique}]{c) In vitro activation technique}\par After liquefaction of human semen, layering activation technique was used according to \hyperref[b18]{Hall, et al. (1995)}, each semen sample was divided into four portions, one portion was considered as a control group by using Hams F-12 medium (Sigma, Germany) and the other three portions of semen is considered as treated groups by adding the following substances: Pentoxifylline (PX) 1mg/ml, L-Carnitine (LC) 0.5 mg/ml and both equally added PX + LC. Certain sperm function parameters were examined following in vitro activation according to WHO (1999) too.\par Statistical analysis: Data from treated and control media groups were expressed as mean ± SEM and statistically analyzed using analysis of variance (ANOVA) to compare the differences between the four prepared media. When F values reach the significant level at 5\%, least significant difference (LSD) test was used \hyperref[b33]{(Sorlie, 1995)}.III. \section[{Results}]{Results}\par Tables 1,2,3 and 4 shows that no significant (P< 0.05) difference in the mean of sperm concentration between control and treated media groups after activation in most infertile patients (asthenozoospermic men,table-1,oligoasthenozoospermic men, table-2, astheno-teratozoospermic men ,table-3 and oligoasthenoteratozoospermic men ,table-4). The activation of human sperm in vitro with both control (Hams F-12) and treated (PX and/or LC) media caused a significant (P<0.05) and a highly significant (P<0.001) increase in the percentage of progressive sperm motility grade (A,B,A+B) compared to before activation by layering activation technique in all treated infertile groups(Tables \hyperref[tab_1]{1,2},3,4). There was a highly significant (P<0.001) increment in the mean of sperm concentration, percentage of progressive sperm motility grade (A), grade (B) and grade (A+B) with the percentage MNS after using mixing PX+LC medium in comparison with using PX and LC alone and with control medium in the asthenozoospermic patients (Table-1) and other mild male factors infertility (Tables \hyperref[tab_2]{2, 3}, 4). Activation of human sperm caused a highly significant (P<0.001) improvement in the MNS in both control and treated group when compared to before activation and between treated semen samples when compared to control semen samples in asthenoteratozoospermic patients(Table-1) and oligoasthenoteratozoospermic (Table-4) patients following layering technique. There was a significant (P<0.05) and a highly significant (P<0.001) decrease in the round cells in both control and treated groups when compared to before activation of all infertile men. Also the results show a highly significant (P<0.001) improvement in the percentage of normal DNA sperms after activation with PX and/or LC by layering technique in most infertile patients. Values are expressed as Mean±SEM. Different small letters mean significant difference at P<0.05. Different capital letters mean significant difference at P<0.001.\par IV. \section[{Discussion}]{Discussion}\par In this study, there was a highly significant increase in the sperm motility grade (A) and grade (A+B), while there was a significant increase in sperm motility grade (B) in treated group. This finding is in agreement with studies that revealed a significant improvement in grade (A), hyperactivation and the acrosome reaction following activation by PX \hyperref[b0]{(Abid, 2005 and}\hyperref[b6]{Al-Dujaily et al., 2007)}. PX has been demonstrated to increase testicular sperm motility when it added to culture media \hyperref[b27]{(Sato and Ishikawa, 2004)}. It inhibits the breakdown of cAMP and it is known that intracellular cAMP concentration plays a central role in cell energy which in turn sustain sperm motility. The increase of cAMP lead to increase progressive sperm motility. The cAMP plays an important role in the glycolytic path way of the sperm and, through its effect on glycolysis. It can influence the energy generation required for sperm motion \hyperref[b35]{(Steiber et al., 2004)}. The highly significant increase in most sperm parameters after adding LC to sperm activated medium which showed a highly elevation in active sperm motility was in agreement with other studies that reported a significant increase in the sperm motility when LC was added to ejaculated human spermatozoa (Al-Dujaily et al.,2012). The other positive effect of LC addition to the medium in current study may be its function to carry fatty acids into the sperm mitochondria to assisting the production of energy. \hyperref[b3]{(Agarwal and Said 2004)}.\par This study believed that the medium contains both LC and PX gave excellent improvement in progressive sperm motility grade (A) and grade (A+B). stated that in vitro administration of LC and PX to extracted testicular sperm samples led to increased sperm motility. Whereas giving a highly improvement results in the percent of MNS may be resulting from the important effect of both PX and/or LC that works as antioxidant ROS scavengers to reduce sperm DNA damage after activation \hyperref[b23]{(Menezo et al.,2007)}.\par Further significant improvement in the percentage of MNS was recorded after activation. This finding may be related to the fast movement of normal spermatozoa from seminal plasma into upper layer of culture medium, and consequently elicited from impact of some seminal plasma components like leukocytes, round cell and others leading to kept the sperm out of stress factor and ROS production that responsible for DNA damage \hyperref[b29]{(Sharma et al., 2004)}. Thus, layering activation technique remove the immotile and dead cells from the sample. The same observation was noticed by other studies using culture for separation and activation of sperm in vitro (Al-Dujaily and Malik, 2013 and Al- \hyperref[b5]{Dujaily et al., 2006)}.\par The results of the present study has found a highly significant reduction in abnormal (DNA damaged) sperms in the infertile semen after activation by all activation media compared with results before activation.This may be caused by the of antioxidants (including LC and PX every one alone or both of them )which added to the medium (HamsF12), PX has been oxygen-free radical scavenging capacities by reducing the superoxide release from human spermatozoa \hyperref[b22]{(McKinney et al.,1996)}.The PX has been shown to decrease ROS production. Moreover, the antioxidant property of LC may also have an influence on sperm motility. L-carnitine, as anti-oxidant \hyperref[b32]{(Solarska et al., 2010)} may protect sperm plasma membrane with high level of unsaturated fatty acid content \hyperref[b4]{(Aitken and Clarkson, 1987)}. Free radicals can also decrease mitochondrial energy availability and impaired sperm motility (De-Lamirande and Gagnon, 1992). It has been emphasized that acridine orange staining of semen smears improve the information obtained by semen analysis with respect to sperm fertilizing capacity \hyperref[b20]{(Kosower et al.,1992)}. The cause of infertility in the infertile men with normal semen parameters could be related to abnormal sperm DNA \hyperref[b23]{(Menezo et al., 2007)}. Therefore, the present work depends on the evaluation of sperm DNA integrity to improve the positive effects of the activation technique and the motility stimulants and to add further information on the quality of spermatozoa that will be used in future on reproductive outcomes \hyperref[b28]{(Schulte et al.,2010)}.\par It was concluded that LC and PX can be added for the medium as activator substances to stimulate certain sperm function parameters in vitro of asthenozoospermic patients with or without other male infertility factors to reduce DNA damage in sperms. This results can be utilized for in vitro activation medium used in the ART centers.\begin{figure}[htbp] \noindent\textbf{1} \par \begin{longtable}{P{0.3245454545454545\textwidth}P{0.02318181818181818\textwidth}P{0.12556818181818183\textwidth}P{0.08982954545454545\textwidth}P{0.09272727272727271\textwidth}P{0.15454545454545454\textwidth}P{0.03960227272727273\textwidth}} \multicolumn{2}{l}{Certain sperm function parameters}\tabcellsep \multicolumn{3}{l}{Before activation hams F12 hams F12 +PX}\tabcellsep LC\tabcellsep PX + LC\\ \multicolumn{2}{l}{Sperm Concentration (Million/ml)}\tabcellsep 53.96±3.77 a\tabcellsep 50.52±3.23 a\tabcellsep 56.29±5.34 a\tabcellsep \multicolumn{2}{l}{58.13±5.49 a 59.78±4.62 a}\\ \tabcellsep Grade A\tabcellsep 4.62±0.89 A\tabcellsep 19.13±2.21 B\tabcellsep 30.86±4.62 B\tabcellsep 29.13±4.2 B\tabcellsep 32.83±3.3 B\\ Active sperm motility (\%)\tabcellsep Grade B Grade A+B\tabcellsep 34.35±1.17 A 38.96±1 A\tabcellsep 39.43±1.85 A 58.57±3.39 B\tabcellsep 42.86±3.34 b 73.71±5.98 Ba\tabcellsep \multicolumn{2}{l}{42.4±2.4 b 71.53±4.88 Ba 77.35±4.13 B 44.52±2.5 B}\\ \multicolumn{2}{l}{Morphologically Normal sperm (\%)}\tabcellsep 35.92±0.81 A\tabcellsep 39.13±1.3 a\tabcellsep 45.57±2.31 b\tabcellsep 46.2±2.42 B\tabcellsep 51.35±2.34 B\\ \multicolumn{2}{l}{Round cells (cell/HPF)}\tabcellsep 7.31±1.2 a\tabcellsep 5±0.94 ab\tabcellsep 3.21±1.28 b\tabcellsep 3.67±1.2 b\tabcellsep 3.96±0.99 b\\ \multicolumn{2}{l}{Green sperm \%}\tabcellsep 50.14±6.51 a\tabcellsep 68.87±6.06 b\tabcellsep 77.74±7.1 b\tabcellsep \multicolumn{2}{l}{66.47±6.99 ab 73.12±6.46 b}\\ \multicolumn{2}{l}{Orange sperm \%}\tabcellsep 49.86±6.51 a\tabcellsep 31.12±6.06 b\tabcellsep 22.25±7.09 b\tabcellsep \multicolumn{2}{l}{33.77±6.92 ab 26.87±6.46 b}\\ \multicolumn{3}{l}{Values are expressed as Mean± SEM.}\tabcellsep \tabcellsep \tabcellsep \\ \multicolumn{4}{l}{Different small letters mean significant difference at P<0.05.}\tabcellsep \tabcellsep \\ \multicolumn{4}{l}{Different capital letters mean significant difference at P<0.001.}\tabcellsep \tabcellsep \end{longtable} \par \caption{\label{tab_0}Table 1 :}\end{figure} \begin{figure}[htbp] \noindent\textbf{2} \par \begin{longtable}{P{0.5743243243243243\textwidth}P{0.07402402402402401\textwidth}P{0.05105105105105105\textwidth}P{0.06381381381381382\textwidth}P{0.038288288288288286\textwidth}P{0.048498498498498493\textwidth}} Certain sperm function parameters\tabcellsep Before activation\tabcellsep hams F12\tabcellsep hams F12 +PX\tabcellsep LC\tabcellsep PX + LC\\ Sperm Concentration (Million/ml)\tabcellsep 10.81±1.22 a\tabcellsep 16.92±3.83 a\tabcellsep 22.70±2.30 Ab\tabcellsep 26.15±2.96 Ab\tabcellsep 32.94±4.16 B\\ \multicolumn{2}{l}{Values are expressed as Mean±SEM.}\tabcellsep \tabcellsep \tabcellsep \tabcellsep \\ \multicolumn{3}{l}{Different small letters mean significant difference at P<0.05.}\tabcellsep \tabcellsep \tabcellsep \\ \multicolumn{3}{l}{Different capital letters mean significant difference at P<0.001.}\tabcellsep \tabcellsep \tabcellsep \end{longtable} \par \caption{\label{tab_1}Table 2 :}\end{figure} \begin{figure}[htbp] \noindent\textbf{3} \par \begin{longtable}{P{0.31839779005524865\textwidth}P{0.022541436464088398\textwidth}P{0.10613259668508288\textwidth}P{0.25922651933701657\textwidth}P{0.021602209944751382\textwidth}P{0.023480662983425413\textwidth}P{0.09861878453038674\textwidth}} \multicolumn{2}{l}{Certain sperm function parameters}\tabcellsep Before activation\tabcellsep hams F12\tabcellsep hams F12 +PX\tabcellsep LC\tabcellsep PX + LC\\ \multicolumn{2}{l}{Sperm Concentration (Million/ml)}\tabcellsep 31.15±2.85 a\tabcellsep \multicolumn{3}{l}{40.96±3.89 a 36.50±5.82 a 37.33±5.52 a}\tabcellsep 59.87±4.59 B\\ \tabcellsep Grade A\tabcellsep 6.58±1.33 A\tabcellsep \multicolumn{3}{l}{18.39±2.10 B 21.71±3.06 B 21.47±3.03 B}\tabcellsep 32.78±2.92 B\\ Active sperm motility (\%)\tabcellsep Grade B Grade A+B\tabcellsep 24.31±1.98 A 30.88±2.48 A\tabcellsep \multicolumn{3}{l}{37.61±2.63 B 36.14±4.62 Ba 36.60±3.13 Ba 56.00±4.20 B 57.86±7.04 B 58.07±5.66 Ba}\tabcellsep 46.65±1.94 B 79.43±3.49 B\\ \multicolumn{2}{l}{Morphologically Normal sperm (\%)}\tabcellsep 19.96±1.29 Aa\tabcellsep \multicolumn{3}{l}{31.26±2.23 b 33.36±4.06 B 36.87±2.97 B}\tabcellsep 52.22±2.56 B\\ Round cells(cell/HPF)\tabcellsep \tabcellsep 7.46±1.44 a\tabcellsep 5.74±1.30 a\tabcellsep 3.07±1.03 b\tabcellsep 6.07±1.76 a\tabcellsep 4.52±1.09 a\\ Green sperm (\%)\tabcellsep \tabcellsep 62.92±6.44 a\tabcellsep \multicolumn{2}{l}{63.77±6.42 a 80.88±6.51 b}\tabcellsep 76.73±6.72 a\tabcellsep 71.22±6.72 ab\\ Orange sperm (\%)\tabcellsep \tabcellsep 37.12±6.43 a\tabcellsep \multicolumn{3}{l}{36.24±6.42 a 19.12±6.51 b 25.26±6.72 a}\tabcellsep 28.77±6.72 ab\\ \multicolumn{3}{l}{Values are expressed as Mean±SEM .}\tabcellsep \tabcellsep \tabcellsep \\ \multicolumn{4}{l}{Different small letters mean significant difference at P<0.05.}\tabcellsep \tabcellsep \\ \multicolumn{4}{l}{Different capital letters mean significant difference at P<0.001.}\tabcellsep \tabcellsep \end{longtable} \par \caption{\label{tab_2}Table 3 :}\end{figure} \begin{figure}[htbp] \noindent\textbf{4} \par \begin{longtable}{P{0.21827445652173913\textwidth}P{0.00577445652173913\textwidth}P{0.03695652173913043\textwidth}P{0.19171195652173914\textwidth}P{0.03580163043478261\textwidth}P{0.12241847826086956\textwidth}P{0.003464673913043478\textwidth}P{0.14436141304347827\textwidth}P{0.09123641304347826\textwidth}} Certain parameters\tabcellsep sperm\tabcellsep function\tabcellsep Before activation\tabcellsep hams F12\tabcellsep hams +PX\tabcellsep F12\tabcellsep LC\tabcellsep PX + LC\\ \multicolumn{3}{l}{Sperm Concentration (Million/ml)}\tabcellsep \multicolumn{2}{l}{12.75±0.76 a 18.24±2.59 ab}\tabcellsep \multicolumn{2}{l}{20.38±2.33 bB}\tabcellsep 21.86±1.78 b\tabcellsep 28.44±3.10 b\\ \tabcellsep \tabcellsep Grade A\tabcellsep 2.60±0.97 A\tabcellsep 15.59±1.55 B\tabcellsep \multicolumn{2}{l}{23.50±2.63 B}\tabcellsep 14.93±1.78 b\tabcellsep 27.89±3.09 B\\ \multicolumn{2}{l}{Active sperm motility (\%)}\tabcellsep Grade B Grade A+B\tabcellsep \multicolumn{2}{l}{19.55±1.46 A 35.18±2.13 B 22.15±1.94 A 50.76±2.99 B}\tabcellsep \multicolumn{2}{l}{37.31±2.80 B 60.81±5.03 B}\tabcellsep \multicolumn{2}{l}{31.57±2.20 Bb 43.33±2.26 B 46.50±3.37 B 71.22±4.77 B}\\ \multicolumn{5}{l}{Morphologically Normal sperm (\%) 21.90±1.17 A 33.47±1.15 B}\tabcellsep \multicolumn{2}{l}{34.38±2.11 B}\tabcellsep 33.79±2.18 B\tabcellsep 41.78±2.74 Ba\\ \multicolumn{2}{l}{Round cells(cell/HPF)}\tabcellsep \tabcellsep 6.65±0.66 A\tabcellsep 2.41±0.49 B\tabcellsep \multicolumn{2}{l}{2.38±0.93 B}\tabcellsep 2.21±0.70 B\tabcellsep 2.94±0.92 B\\ \multicolumn{2}{l}{Green sperm (\%)}\tabcellsep \tabcellsep \multicolumn{2}{l}{21.02±4.65 A 51.82±6.52 B}\tabcellsep \multicolumn{2}{l}{62.43±6.56 B}\tabcellsep 68.91±4.27 B\tabcellsep 74.71±5.55 B\\ \multicolumn{2}{l}{Orange sperm (\%)}\tabcellsep \tabcellsep \multicolumn{2}{l}{78.97±4.65 A 48.17±6.52 B}\tabcellsep \multicolumn{2}{l}{37.56±6.56 Ba}\tabcellsep 31.08±4.27 B\tabcellsep 25.29±5.55 B\end{longtable} \par \caption{\label{tab_3}Table 4 :}\end{figure} \footnote{© 2013 Global Journals Inc. (US) © 2013 Global Journals Inc. (US)} \backmatter \begin{bibitemlist}{1} \bibitem[Tejada et al. ()]{b36}\label{b36} ‘A test for the practical evaluation of male fertility by acridine orange (AO) fluorescence’. R I Tejada , J C Mitchell , A Norman , J J Marik , S Friedman . \textit{Fertil.Steril} 1984. 42 p. . \bibitem[Menezo et al. ()]{b23}\label{b23} ‘Antioxidants to reduce sperm DNA fragmentation: an unexpected adverse effect’. Y J Menezo , A Hazout , G Panteix , F Robert , J Rollet , P Cohen-Bacrie . \textit{Reprod Biomed Online} 2007. 14 p. . \bibitem[Lambardo et al. ()]{b21}\label{b21} ‘Antisperm immunity in assisted reproduction’. F Lambardo , L Gandini , A Lenzi , F Dondero . \textit{J Reprod Immunol} 2004. 62 p. . \bibitem[Agarwal and Said ()]{b3}\label{b3} ‘Carnitine and male infertiity’. A Agarwal , T M Said . \textit{Reprod. Biomed} 2004. 8 p. . \bibitem[Steiber et al. ()]{b35}\label{b35} ‘Carnitine: a nutritional, biosynthetic, and functional perspective’. A Steiber , J Kerner , C Hoppelm . \textit{Mol Aspects Med} 2004. 25 (5-6) p. . \bibitem[Aitken and Clarkson ()]{b4}\label{b4} ‘Cellular basis of defective sperm function and its association with the genesis of reactive oxygen species by human spermatozoa’. R J Aitken , J S Clarkson . \textit{J. Reprod.Fertil} 1987. 18 p. . \bibitem[Sills et al. ()]{b31}\label{b31} ‘Chromatin fluorescence characteristics and standard semen analysis parameters correlations observed in andrology testing among 136 males referred for infertility evaluation’. E S Sills , J T Fryman , M Perloe , K B Michels , M J Tucker . \textit{J. Obstet. Gynaecol} 2004. 24 p. . \bibitem[Cocuzza et al. ()]{b13}\label{b13} ‘Clinical relevance of oxidative stress and sperm chromatin damage in male infertility: an evidence based analysis’. M Cocuzza , S C Sikka , K S Athayde . \textit{Int.braz J.urol} 2007. 33 (5) p. . \bibitem[Gil-Guzman et al. ()]{b17}\label{b17} ‘Differential production of reactive oxygen species by subsets of human spermatozoa at different stages of maturation’. E Gil-Guzman , M Ollero , M C Lopez . \textit{Hum.Reprod} 2001. 16 p. . \bibitem[Al-Dujaily et al. ()]{b5}\label{b5} ‘Effect of Glycyrrhiza extract on in vitro sperm activation of asthenospermic patients’. S S Al-Dujaily , A S Al-Janabi , M Nori . \textit{J Babylon University} 2006. 11 p. . \bibitem[Al-Dujaily et al. ()]{b7}\label{b7} ‘Effect of L-carnitine on in vitro sperm activation of infertile men’. S S Al-Dujaily , N Al-Shahiri , A Abbas . \textit{I J Embryo inter Res} 2012. 2 (3) p. . \bibitem[Abid ()]{b0}\label{b0} \textit{Effect of pentoxifylline (Trental®) on human sperm in vitro activation of asthenospermic infertile patients}, R S Abid . 2005. High diploma thesis Institute of Embryo Research on Infertility Treatment/ Al-Nahrian University \bibitem[Stanic et al. ()]{b34}\label{b34} ‘Effect of pentoxifylline on motility and membrane integrity of cryopreservation human spermatozoa’. P Stanic , Z Sonicki , E Suchanek . \textit{International J Androl} 2002. 25 p. . \bibitem[Al-Dujaily et al. ()]{b6}\label{b6} ‘Effect of pentoxifylline on the outcome of artificial inseminations. Iraqi post graduate’. S S Al-Dujaily , A R Al-Nakash , S A Al-Biaty . \textit{Med J} 2007. 5 p. . \bibitem[Aliabadi et al. ()]{b1}\label{b1} ‘Effects of l-carnitine and pentoxifylline on the activity of lactate dehydrogenase C4 isozyme and motility of testicular spermatozoa in mice’. E Aliabadi , F Karimi , M Rasti , M Akmali , T Esmaeilpour . \textit{J Reprod Infertil} 2013. 14 (2) p. . \bibitem[Muller et al. ()]{b24}\label{b24} ‘Effects of oral l-carnitine supplementation on in vivo long-chain fatty acid oxidation in healthy adults’. D M Muller , H Seim , W Kiess , H Loster , T Richter . \textit{Univ. Leipzig, Children's Hospital, Germany. Metabolism} 2002. 51 (11) p. . \bibitem[Agarwal and Kulkarni ()]{b2}\label{b2} ‘Efficacy and safety of semen in patient with oligospermia: an open clinical study’. H S Agarwal , K S Kulkarni . \textit{Indian J. Clin. Practice} 2003. 14 (2) p. . \bibitem[Sorlie ()]{b33}\label{b33} ‘Examination and Board Review’. D E Sorlie . \textit{Medical Biostatistics and Epidemiology} 1995. p. . Appleton and Lang Norwalk Connecticut (1st ed.) \bibitem[Okada et al. ()]{b25}\label{b25} ‘Formation of reaction oxygen species by spermatozoa from asthenospermic patients: response to treatment with pentoxifylline’. H Okada , N Tatsumi , M Kanzaki . \textit{J Urology} 1997. 157 p. . \bibitem[Dohle et al. ()]{b16}\label{b16} ‘Guide line on male infertility’. G R Dohle , A Jungwirth , G Colpi , T Diemer . \textit{Eur Associat Urol} 2007. 11 p. . \bibitem[Twigg et al. ()]{b37}\label{b37} ‘Iatrogenic DNA damage induced in human spermatozoa during sperm preparation: protective significance of seminal plasma’. J Twigg , D S Irvine , P Houston , N Fulton , L Michael , R J Aitken . \textit{Mol Hum Reprod} 1998. 4 p. . \bibitem[Al-Dujaily and Malik ()]{b8}\label{b8} ‘In vitro sperm activation for asthenospermic semen by using progesterone, pentoxifylline and Glycyrrhiza glabra extraction.Globel’. S S Al-Dujaily , K Malik . \textit{J Med Res} 2013. 3 (1) p. . \bibitem[Diemer et al. ()]{b15}\label{b15} ‘Influence of urogenital infection on sperm function’. T Diemer , M Ludwig , P Huwe , D B Hales . \textit{Curr. Opin. Urol} 2000. 10 p. . \bibitem[Hall et al. ()]{b18}\label{b18} ‘Intracytoplasmic sperm injection versus high insemination concentration in vitro fertilization in cases of very severe teratozoospermia’. J Hall , S Fishel , S Green , S Fleming , A Hunter , N Stoddert , K Dowell , S Thornton . \textit{Hum Reprod} 1995. 10 p. . \bibitem[Health Organization Who) ()]{b38}\label{b38} ‘Laboratory Manual for the examination of Human Semen and Sperm-Cervical Mucus Interaction’. UK.: 4-59. 40. \textit{Laboratory Manual for Examination and Processing of Human Semen}, World Health Organization, ( Who) (ed.) (New York; Switzerland) 1999. 2010. Press. p. 37. (4th ed. 5th ed) \bibitem[Oosterhuis et al. ()]{b26}\label{b26} ‘Measuring apoptosis in human spermatozoa a biological assay for semen quality’. G J Oosterhuis , A B Mulder , E Kalsbeek-Batenburg , C B Lambalk , J Schoemaker , I Vermes . \textit{Fertil.Steril} 2000. 74 p. . \bibitem[Men's health American Society for Reproductive Medicine (ASRM) ()]{b10}\label{b10} ‘Men's health’. \textit{American Society for Reproductive Medicine (ASRM)} 2010. UMMC) Press. p. . Maryland University of Maryland Medical Center \bibitem[Alvarez ()]{b9}\label{b9} ‘Nuture vs nature: how can we optimize sperm quality?’. J G Alvarez . \textit{J.Androl} 2003. 24 p. . \bibitem[Aviad and Dettelbache ()]{b11}\label{b11} ‘Pharmacology of Pentoxifylline a heamorheologic agent for the treatment of intermittent claudication’. D M Aviad , H R Dettelbache . \textit{Angiol} 1984. 35 p. . \bibitem[De-Lamirande and Gagnon ()]{b14}\label{b14} ‘Reactive oxygen species and human spermatozoa. ll depletion of adenosine triphosphate plays an important role in the inhibition of sperm motility’. E De-Lamirande , C Gagnon . \textit{J. Androl} 1992. 13 p. . \bibitem[Sikka ()]{b30}\label{b30} ‘Relative impact of oxidative stress on male reproductive function’. S C Sikka . \textit{Curr. Med. Chem} 2001. 8 p. . \bibitem[Claudette and Lawrence ()]{b12}\label{b12} ‘Role of free l-carnitine and acetyl-l-carnitine in post-gonadal maturation of mammalian spermatozoa’. J Claudette , M L Lawrence . \textit{Human Reprod} 1996. 2 (2) p. . \bibitem[Sato and Ishikawa ()]{b27}\label{b27} ‘Room temperature storage of mouse epididymal spermatozoa: exploration of factors affecting sperm survival’. M Sato , A Ishikawa . \textit{Theriogenology} 2004. 61 (7-8) p. . \bibitem[Sharma et al. ()]{b29}\label{b29} ‘Sperm DNA damage and its clinical relevance in assessing reproductive outcome’. R K Sharma , T Said , A Agarwal . \textit{Asian. J. Androl} 2004. 6 p. . \bibitem[Schulte et al. ()]{b28}\label{b28} ‘Sperm DNA damage in male infertility: etiologies, assays, and outcomes’. R T Schulte , D A Ohl , M Sigman , G D Smith . \textit{J. Assist. Reprod. Genet} 2010. 27 p. . \bibitem[Henkel and Schill ()]{b19}\label{b19} ‘Sperm preparation for ART’. R Henkel , W Schill . \textit{Reprod Biol And Endocr} 2003. 1 p. . \bibitem[Solarska et al. ()]{b32}\label{b32} ‘The antioxidant properties of carnitine in vitro’. K Solarska , A Lewinska , A Karowicz-Bilinska , G Bartosz . \textit{Cell. Mol. Biol. Lett} 2010. 15 p. . \bibitem[Mckinney et al. ()]{b22}\label{b22} ‘The effect of pentoxifylline on the generation of reactive oxygen species and lipid peroxidation in human spermatozoa’. K A Mckinney , S E M Lewis , W Thompson . \textit{Andrologia. J} 1996. 28 p. . \bibitem[Kosower et al. ()]{b20}\label{b20} ‘Thiol-disulfide status and acridine orange fluorescence of mammalian sperm nuclei’. N S Kosower , H Katayose , R J N Yanagimachi . \textit{J. Androl} 1992. 13 p. . \end{bibitemlist} \end{document}